Search
Close this search box.

Boyds adds medical writer, Vicky Wheeldon, to growing Regulatory Affairs team

We are delighted to announce the appointment of experienced clinical researcher Vicky Wheeldon as Associate Medical Writer in response to sustained demand for our dedicated regulatory services. 

With a degree in Biochemistry, Vicky first qualified as a children’s nurse, specialising in oncology and working in the child and teenage cancer unit at the Royal Victoria Infirmary, Newcastle. She then moved into clinical research and, over the last 15 years, has held several roles including study coordinator, trial manager, R&D quality assurance manager, and paediatric research team lead.

At Boyds, Vicky will work closely with members of the regulatory, clinical and product development teams in the production of documentation, from early-stage clinical development to marketing authorisations and beyond.

Of her appointment, Vicky said: “I was attracted to the role at Boyds as it provides a great opportunity for me to move back into the commercial environment as well as get involved in a growing business with a patient-focused ethos and an excellent reputation in the industry. I’m particularly interested in Boyds’ work supporting PIPs (paediatric investigation plans), having seen the benefit of the introduction of novel treatments for childhood conditions first-hand through my clinical work.”

Boyds has recently embarked on a large recruitment drive to increase capacity, capabilities and expertise as demand for our services continues to grow across the UK, US and Europe.

Dr Julie Warner, Vice President of Regulatory Affairs at Boyds, added: “Vicky’s varied, unique career background enables her to view clinical research from the perspective of both an industry professional and healthcare professional. With extensive experience of working on both commercial and non-commercial studies across multiple clinical specialities, Vicky will be an immediate asset to the team and add real value to overall client experience.”

Facebook
Twitter
LinkedIn